Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Subjects

Subjects :

Diseases of the blood and blood-forming organs
RC633-647.5
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Details

Language :

English

ISSN :

17568722

Volume :

16

Issue :

1

Database :

Directory of Open Access Journals

Journal :

Journal of Hematology & Oncology

Publication Type :

Academic Journal

Accession number :

edsdoj.17a094e845904da9b5ec535a924799e9

Document Type :

article

Full Text :

https://doi.org/10.1186/s13045-023-01414-8